<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38585665</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-0042</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>19</Day></PubDate></JournalIssue><Title>iScience</Title><ISOAbbreviation>iScience</ISOAbbreviation></Journal><ArticleTitle>Long COVID across SARS-CoV-2 variants, lineages, and sublineages.</ArticleTitle><Pagination><StartPage>109536</StartPage><MedlinePgn>109536</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">109536</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.isci.2024.109536</ELocationID><Abstract><AbstractText>This prospective study aimed to determine the prevalence of long COVID in patients hospitalized for SARS-CoV-2 infection from March 2020 to July 2022 and assess the impact of different viral lineages. A total of 2,524 patients were followed up for 12&#xa0;months, with persistent symptoms reported in 35.2% at one month, decreasing thereafter. Omicron variant patients initially showed higher symptom intensity, but this trend diminished over time. Certain viral lineages, notably Delta lineages AY.126 and AY.43, and Omicron sublineages BA.1.17, BA.2.56, and BA.5.1, consistently correlated with more severe symptoms. Overall, long COVID prevalence and severity were similar across SARS-CoV-2 variants. Specific lineages may influence post-COVID sequelae persistence and severity.</AbstractText><CopyrightInformation>&#xa9; 2024 Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Padilla</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad Miguel Hern&#xe1;ndez de Elche, San Juan de Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ledesma</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Abell&#xe1;n</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad Miguel Hern&#xe1;ndez de Elche, San Juan de Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>Jos&#xe9; Alberto</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Gonz&#xe1;lez</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Rica</LastName><ForeName>Alba</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Microbiology Service, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galiana</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Microbiology Service, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guti&#xe9;rrez</LastName><ForeName>F&#xe9;lix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad Miguel Hern&#xe1;ndez de Elche, San Juan de Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masi&#xe1;</LastName><ForeName>Mar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad Miguel Hern&#xe1;ndez de Elche, San Juan de Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>iScience</MedlineTA><NlmUniqueID>101724038</NlmUniqueID><ISSNLinking>2589-0042</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biological sciences</Keyword><Keyword MajorTopicYN="N">Microbial genomics</Keyword><Keyword MajorTopicYN="N">Microbiology</Keyword><Keyword MajorTopicYN="N">Virology</Keyword></KeywordList><CoiStatement>None to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>8</Day><Hour>4</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38585665</ArticleId><ArticleId IdType="pmc">PMC10995878</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2024.109536</ArticleId><ArticleId IdType="pii">S2589-0042(24)00758-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Markov P.V., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N.I., Katzourakis A. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023;21:361&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu A., Hong B., Lou F., Wang S., Li W., Shafqat A., An X., Zhao Y., Song L., Tong Y., Fan H. Sub-lineages of the SARS-CoV-2 Omicron variants: Characteristics and prevention. MedComm. 2022;3:e172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9380698</ArticleId><ArticleId IdType="pubmed">35992968</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg T., Ferguson N.M., Nash S.G., Webster H.H., Flaxman S., Andrews N., Hinsley W., Bernal J.L., Kall M., Bhatt S., et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399:1303&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926413</ArticleId><ArticleId IdType="pubmed">35305296</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Pujol J.C., Spector T.D., Ourselin S., Steves C.J. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263&#x2013;2264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortellini A., Tabernero J., Mukherjee U., Salazar R., Sureda A., Maluquer C., Ferrante D., Bower M., Sharkey R., Mirallas O., et al. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry. Lancet Oncol. 2023;24:335&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9991062</ArticleId><ArticleId IdType="pubmed">36898391</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlert C.R., Strahm C., G&#xfc;sewell S., Cusini A., Brucher A., Goppel S., M&#xf6;ller E., M&#xf6;ller J.C., Ortner M., Ruetti M., et al. Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study. Clin. Infect. Dis. 2023;77:194&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10371307</ArticleId><ArticleId IdType="pubmed">36905145</ArticleId></ArticleIdList></Reference><Reference><Citation>Willan J., Agarwal G., Bienz N. Mortality and burden of post-COVID-19 syndrome have reduced with time across SARS-CoV-2 variants in haematology patients. Br. J. Haematol. 2023;201:640&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">36861893</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H.G., Honerlaw J.P., Maripuri M., Samayamuthu M.J., Beaulieu-Jones B.R., Baig H.S., L'Yi S., Ho Y.L., Morris M., Panickan V.A., et al. Potential pitfalls in the use of real-world data for studying long COVID. Nat. Med. 2023;29:1040&#x2013;1043. doi: 10.1038/s41591-023-02274-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02274-y</ArticleId><ArticleId IdType="pmc">PMC10205658</ArticleId><ArticleId IdType="pubmed">37055567</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjun M.C., Singh A.K., Pal D., Das K., Alekhya G., Venkateshan M., Mishra B., Patro B.K., Mohapatra P.R., Subba S.H. Characteristics and predictors of Long&#xa0;COVID among diagnosed cases of COVID-19. PLoS One. 2022;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9767341</ArticleId><ArticleId IdType="pubmed">36538532</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S., Rosell A., Phillipson M., Mangsbo S.M., Nilsson P., Hober S., Th&#xe5;lin C. Symptoms and functional impairment assessed 8&#xa0;months after mild COVID-19 among health care workers. JAMA. 2021;325:2015&#x2013;2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8027932</ArticleId><ArticleId IdType="pubmed">33825846</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M., Elliott J., Chadeau-Hyam M., Riley S., Darzi A., Cooke G., Ward H., Elliott P. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat. Commun. 2022;13:1957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re'em Y., Redfield S., Austin J.P., Akrami A. Characterizing long COVID in an international cohort: 7&#xa0;months of symptoms and their impact. EClinicalMedicine. 2021;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T., Jolley S.E., Karlson E.W., Levitan E.B., Levy B., McComsey G.A., McCorkell L., Nadkarni G.N., Parthasarathy S., Singh U., et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023;329:1934&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics (ONS)  ONS website, statistical bulletin, Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 30 March 2023. 2023. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/previousReleases</Citation></Reference><Reference><Citation>Strahm C., Seneghini M., G&#xfc;sewell S., Egger T., Leal-Neto O., Brucher A., Lemmenmeier E., Meier Kleeb D., M&#xf6;ller J.C., Rieder P., et al. Symptoms compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection&#x2014;results of a prospective multicenter cohort. Clin. Infect. Dis. 2022;75:e1011&#x2013;e1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9383387</ArticleId><ArticleId IdType="pubmed">35090015</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahmer T., Borzikowsky C., Lieb W., Horn A., Krist L., Fricke J., Scheibenbogen C., Rabe K.F., Maetzler W., Maetzler C., et al. Severity, predictors and clinical correlates of post-COVID syndrome (PCS) in Germany: a prospective, multi-centre, population-based cohort study. EClinicalMedicine. 2022;51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9289961</ArticleId><ArticleId IdType="pubmed">35875815</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Aceituno A., Garc&#xed;a-Hern&#xe1;ndez A., Larumbe-Zabala E. COVID-19 long-term sequelae: Omicron versus Alpha and Delta variants. Infect. Dis. Now. 2023;53</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9970656</ArticleId><ArticleId IdType="pubmed">36858287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B., Xie Y., Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat. Med. 2022;28:2398&#x2013;2405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell C.D., Lone N.I., Baillie J.K. Comorbidities, multimorbidity and COVID-19. Nat. Med. 2023;29:334&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">36797482</ArticleId></ArticleIdList></Reference><Reference><Citation>El Moussaoui R., Opmeer B.C., de Borgie C.A.J.M., Nieuwkerk P., Bossuyt P.M.M., Speelman P., Prins J.M. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia. Chest. 2006;130:1165&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035452</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T., Menges D., Anagnostopoulos A., Domenghino A., Aschmann H.E., Frei A., Fehr J.S., Puhan M.A. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population-based, longitudinal cohort study. BMJ. 2023;381</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10230608</ArticleId><ArticleId IdType="pubmed">37257891</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V.-T., Porcher R., Pane I., Ravaud P. Course of post covid-19 disease symptoms over time in the ComPaRe long covid prospective e-cohort. Nat. Commun. 2022;13:1812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8983754</ArticleId><ArticleId IdType="pubmed">35383197</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter R.S., Nieters A., Kr&#xe4;usslich H.G., Brockmann S.O., G&#xf6;pel S., Kindle G., Merle U., Steinacker J.M., Rothenbacher D., Kern W.V., EPILOC Phase 1 Study Group Post-acute sequelae of covid-19 six to 12&#xa0;months after infection: population based study. BMJ. 2022;379</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9557001</ArticleId><ArticleId IdType="pubmed">36229057</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Zhao H., Esp&#xed;n E., Tebbutt S.J. Association of SARS-CoV-2 infection and persistence with long COVID. Lancet Respir. Med. 2023;11:504&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10171832</ArticleId><ArticleId IdType="pubmed">37178694</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Zhao H., Shannon C.P., Tebbutt S.J. Omicron variants of SARS-CoV-2 and long COVID. Front. Immunol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9780375</ArticleId><ArticleId IdType="pubmed">36569883</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan D.J., Franchini M., Joyner M.J., Casadevall A., Focosi D. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. Nat. Commun. 2022;13:6478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9617541</ArticleId><ArticleId IdType="pubmed">36309490</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren O., Stehlik P., Clark J., Alcorn K., Glasziou P. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med. 2023;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Guill&#xe9;n L., Padilla S., Fern&#xe1;ndez M., Agull&#xf3; V., Garc&#xed;a J.A., Telenti G., Garc&#xed;a-Abell&#xe1;n J., Botella &#xc1;., Guti&#xe9;rrez F., Masi&#xe1; M. Preemptive interleukin-6 blockade in patients with COVID-19. Sci. Rep. 2020;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7545205</ArticleId><ArticleId IdType="pubmed">33033405</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19. National Institute for Health and Care Excellence (NICE); London: 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Masi&#xe1; M., Fern&#xe1;ndez-Gonz&#xe1;lez M., Garc&#xed;a J.A., Padilla S., Garc&#xed;a-Abell&#xe1;n J., Botella &#xc1;., Mascarell P., Agull&#xf3; V., Guti&#xe9;rrez F. Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade. EBioMedicine. 2022;82</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9265168</ArticleId><ArticleId IdType="pubmed">35816896</ArticleId></ArticleIdList></Reference><Reference><Citation>Websites: Liaison SARS-CoV-2 Trimerics IgG assay brochure. https://artemisialab.it/wp-content/uploads/2021/03/liaisonr_sars-cov-2_trimerics_igg_assay_m0870004408_lr_digital.pdf.</Citation></Reference><Reference><Citation>Fern&#xe1;ndez-Gonz&#xe1;lez M., Agull&#xf3; V., Garc&#xed;a J.A., Padilla S., Garc&#xed;a-Abell&#xe1;n J., de la Rica A., Mascarell P., Masi&#xe1; M., Guti&#xe9;rrez F. T-cell immunity against SARS-CoV-2 measured by an interferon-&#x3b3; release assay is strongly associated with patient outcomes in vaccinated persons hospitalized with Delta or Omicron variants. J.&#xa0;Infect. Dis. 2023;7</Citation><ArticleIdList><ArticleId IdType="pubmed">37418551</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J., Padilla S., Fern&#xe1;ndez-Gonz&#xe1;lez M., Garc&#xed;a J.A., Agull&#xf3; V., Andreo M., Ruiz S., Galiana A., Guti&#xe9;rrez F., Masi&#xe1; M. Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study. J.&#xa0;Clin. Immunol. 2021;41:1490&#x2013;1501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>